Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Long-Term Investments (2010 - 2026)

Exelixis (EXEL) posted quarterly Long-Term Investments of $649.1 million for Q2 2026, up 4.8% year-over-year from $619.4 million in Q2 2025, and up 7.54% quarter-over-quarter from $603.6 million in Q1 2026.

Analysis

Exelixis (EXEL) Long-Term Investments (2010 - 2026) Analysis & Trends

Exelixis' Long-Term Investments history runs 17 years deep, the most recent figure standing at $649.1 million for Q2 2026.

  • In Q2 2026, Long-Term Investments rose 4.8% year-over-year to $649.1 million; the TTM figure through Apr 2026 stood at $649.1 million (up 4.8% YoY), while the FY2026 annual figure was $603.6 million, down 5.29% from the prior year.
  • Long-Term Investments for Q2 2026 stood at $649.1 million, up from $603.6 million in the prior quarter.
  • The five-year high for Long-Term Investments was $838.6 million in Q2 2023, with the low at $404.5 million in Q2 2022.
  • The 5-year median for Long-Term Investments is $619.4 million (2025), against an average of $625.3 million.
  • The sharpest annual moves came in 2022 and 2024: Long-Term Investments soared 103.91% in 2022, then tumbled 48.45% in 2024.
  • Exelixis' Long-Term Investments stood at $756.7 million in 2022, then decreased by 3.7% to $728.7 million in 2023, then slipped by 28.17% to $523.4 million in 2024, then grew by 10.48% to $578.3 million in 2025, then advanced by 12.25% to $649.1 million in 2026.
  • Business Quant data shows EXEL's Long-Term Investments at $649.1 million in Q2 2026, $603.6 million in Q1 2026, and $578.3 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -4.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 1.77 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 22.17 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 372.10 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn 544.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 544.93 Mn
Apr 3, 2026 649.14 Mn
Jan 2, 2026 603.60 Mn
Oct 3, 2025 578.29 Mn
Jul 4, 2025 594.65 Mn
Apr 4, 2025 619.44 Mn
Jan 3, 2025 637.29 Mn
Sep 27, 2024 523.42 Mn
Jun 28, 2024 432.31 Mn
Mar 29, 2024 629.56 Mn
Dec 29, 2023 728.72 Mn
Sep 29, 2023 811.68 Mn
Jun 30, 2023 838.62 Mn
Mar 31, 2023 806.62 Mn
Dec 30, 2022 756.73 Mn
Sep 30, 2022 551.74 Mn
Jul 1, 2022 463.89 Mn
Apr 1, 2022 404.54 Mn
Dec 31, 2021 371.11 Mn
Oct 1, 2021 362.22 Mn